Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel
Condition(s):Breast CancerLast Updated:August 17, 2020Unknown status
Hide Studies Not Open or Pending
Condition(s):Breast CancerLast Updated:August 17, 2020Unknown status
Condition(s):Solid Tumor; Haematological Malignancy; Colorectal Neoplasms; Urinary Bladder Neoplasm; Gallbladder Neoplasms; Salivary Gland Neoplasm; Lung Neoplasm; Pancreatic Neoplasm; Ovarian Neoplasms; Prostatic Neoplasm; Skin NeoplasmLast Updated:October 25, 2023Recruiting
Condition(s):Metastatic Breast CancerLast Updated:December 7, 2021Completed
Condition(s):Healthy MenLast Updated:February 28, 2024Active, not recruiting
Condition(s):HER2-positive Carcinoma; HER2-positive Primary MalignancyLast Updated:April 17, 2018Completed
Condition(s):Solid CancersLast Updated:June 11, 2015Completed
Condition(s):Non-small Cell Lung CancerLast Updated:July 7, 2015Completed
Condition(s):Solid TumorLast Updated:March 5, 2024Active, not recruiting
Condition(s):Breast CancerLast Updated:June 27, 2023Active, not recruiting
Condition(s):Breast CancerLast Updated:January 11, 2024Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.